Howson preempts Qilu! AstraZeneta's heavy sugar-lowering drug is under siege from domestic giants.

Figure 1: Registration of Shagritin tablets by Haussen Pharmaceuticals Source: NMPA Image caption AstraZeneta's global sales of Shagritin (in millions of dollars) Source: Miennet multinational listed company sales database Shagritin is II Peptidease-4 (DPP-4) competitive inhibitors can reduce the rate of infestation of enteric trypsin and increase its blood concentration, thereby reducing the blood sugar levels of patients with type 2 diabetes on an empty stomach and after meals in a glucose-dependent manner.
Shagritin was first developed by Squire and later acquired by AstraZeneta, with global sales peaking at $888 million in 2013 and then falling, with global sales of just $527 million in 2019.
figure 3: Sales of AstraZeneta's Shagritin terminals in China Source: Minnet China's public medical institutions terminal competition pattern The original research products were approved for listing in China in 2011 and began to sell in 2017 after entering the national health insurance directory.
From the channel pattern, AstraZeneta's main layout in the city public hospitals and county-level public hospitals, the last two years in the urban community center layout is also very dazzling, the current domestic approved enterprises have Osaikang and Zhengda Sunny, the product after the market how to adjust the strategic layout, worthy of follow-up attention.
figure 4: Declaration of shagritin film imitation listed enterprises Source: Minet MED2.0 China Drug Review Database Haussen's listing application, if successfully approved, will become the third (and as if reviewed), and Qilu pharmaceutical declaration time is late, the relevant acceptance number is currently being reviewed and approved.
table 1: 2018 to date Howson Pharmaceutical Group has been approved for listing of digestive systems and metabolic drugs Source: MED2.0 China Drug Review Database 2018 to date, Howson Pharmaceuticals Group has been approved for listing of six digestive systems and metabolic drugs, four of which are diabetes drugs.
Among them, polyethyl glycol locena peptide injections for a new class of drugs, Ngre net tablets, kaglile net tablets and Viglitin tablets have taken the first imitation, this shagritin tablets, if successfully approved, will continue to expand the company's layout in the field of diabetes drugs.
source: NMPA official website, MiNet database.